NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 D-cycloserine and Lurasidone, an oral, fixed dosed combination of D-cycloserine/lurasidone that earned food and drug administration-designated as breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 ketamine, which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior ASIB. The company has a partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Market Cap	$109.77M	P/E Ratio	N/A
52W High	$3.84	52W Low	$1.62
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	51.8%	52W Position	123.4%
Overall Score	52	Value Score	40
Quality Score	26	Technical Score	90

EPS Current Est	$-0.12	EPS Next Est	$0.87
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRXP	$4.36	+35.40%	3.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NRXP	$4.36	+35.4%	3.04M
3
4
5
6

NRXP

NRXP

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get NRX Pharmaceuticals Inc. Data in Excel

Get NRX Pharmaceuticals Inc. Data in Excel